FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, namely to a multi-domain binding molecule capable of binding a peptide-major histocompatibility complex (pMHC), which contains a pMHC binding fragment, which is associated with an immune effector that attracts T-cells, and a domain which increases half-life, containing an immunoglobulin Fc or an albumin binding domain, a composition containing the same, as well as a method for preparing the same. Also disclosed is an expression vector containing a nucleic acid coding said multi-domain binding molecule, as well as a cell containing said vector.
EFFECT: invention is effective for treating cancer or tumour.
14 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
